Susan Alice Cowan

Susan Alice Cowan

Auto-generated profile, based on publicly available information

Susan Alice Cowan

Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in The Lancet HIV
Verified
Journal Article
Closed access
LTLara Tavoschi
Lara Tavoschi
JDJoana Gomes Dias
Joana Gomes Dias
APAnastasia Pharris
Anastasia Pharris
DSDaniela Schmid
Daniela Schmid
ASAndré Sasse
André Sasse
VDValerie Delpech
Valerie Delpech

10 December 2015 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JDJessika Deblonde
Jessika Deblonde
ASAndré Sasse
André Sasse
JAJulia Del Amo
Julia Del Amo
FBFiona Burns
Fiona Burns
VDValerie Delpech
Valerie Delpech
TNTeymur Noori
Teymur Noori
In the European Union/European Economic Area (EU/EEA), migrants from high-endemic countries are disproportionately affected by HIV. Between 2007 and 2012, migrants represented 39 % of reported HIV cases. There is growing evidence that a significant proportion of HIV acquisition among migrant populations occurs after their arrival in Europe. Migrants are confronted with multiple risk factors that shape patterns of population HIV susceptibility and vulnerability, which simultaneously affect HIV transmission. Undocumented migrants incur additional risks for contracting HIV due to limited access to adequate health care services, protection and justice, alongside insecure housing and employment conditions. All EU/EEA countries have ratified a number of international and regional human rights instruments that enshrine access to health care as a human right that should be available to everyone without discrimination. From a clinical and public health perspective, early HIV care and treatment is associated with viral suppression, improved health outcomes and reductions in transmission risks. A current challenge of the HIV epidemic is to reach the highest proportion of overall viral suppression among people living with HIV in order to impact on HIV transmission. Although the majority of EU/EEA countries regard migrants as an important sub-population for their national responses to HIV, and despite the overwhelming evidence of the individual and public health benefits associated with HIV care and treatment, a significant number of EU/EEA countries do not provide antiretroviral treatment to undocumented migrants. HIV transmission dynamics in migrant populations depend on the respective weight of all risk and vulnerability factors to which they are exposed, which act together in a synergistic way. People who are not linked to HIV care will continue to unwillingly contribute to the on-going transmission of HIV. Following the recommendations of the European Union Agency for Fundamental Rights, ensuring access to HIV-care for all sub-populations, including undocumented migrants, would fulfil the human rights of those populations and also strengthen the control of HIV incidence among those not currently able to access HIV care.

6 August 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PCPeer Brehm Christensen
Peer Brehm Christensen
GHGordon Hay
Gordon Hay
PJPeter Jepsen
Peter Jepsen
LOLars Haukali Omland
Lars Haukali Omland
SJSøren Andreas Just
Søren Andreas Just
SCSusan Cowan
Susan Cowan
A national survey for chronic hepatitis C has not been performed in Denmark and the prevalence is unknown. Our aim was to estimate the prevalence of chronic hepatitis C from public registers and the proportion of these patients who received specialized healthcare.

20 March 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AGAnnabelle Gourlay
Annabelle Gourlay
TNTeymur Noori
Teymur Noori
APAnastasia Pharris
Anastasia Pharris
MAMaria Axelsson
Maria Axelsson
DCDominique Costagliola
Dominique Costagliola
KPKholoud Porter
Kholoud Porter
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set a “90-90-90” target to curb the human immunodeficiency virus (HIV) epidemic by 2020, but methods used to assess whether countries have reached this target are not standardized, hindering comparisons. Through a collaboration formed by the European Centre for Disease Prevention and Control (ECDC) with European HIV cohorts and surveillance agencies, we constructed a standardized, 4-stage continuum of HIV care for 11 European Union countries for 2013. Stages were defined as (1) number of people living with HIV in the country by end of 2013; (2) proportion of stage 1 ever diagnosed; (3) proportion of stage 2 that ever initiated ART; and (4) proportion of stage 3 who became virally suppressed (≤200 copies/mL). Case surveillance data were used primarily to derive stages 1 (using back-calculation models) and 2, and cohort data for stages 3 and 4. In 2013, 674500 people in the 11 countries were estimated to be living with HIV, ranging from 5500 to 153400 in each country. Overall HIV prevalence was 0.22% (range, 0.09%–0.36%). Overall proportions of each previous stage were 84% diagnosed, 84% on ART, and 85% virally suppressed (60% of people living with HIV). Two countries achieved ≥90% for all stages, and more than half had reached ≥90% for at least 1 stage. European Union countries are nearing the 90-90-90 target. Reducing the proportion undiagnosed remains the greatest barrier to achieving this target, suggesting that further efforts are needed to improve HIV testing rates. Standardizing methods to derive comparable continuums of care remains a challenge.

13 December 2023 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
CTChristos Thomadakis
Christos Thomadakis
IGIlias Gountas
Ilias Gountas
EDErika Duffell
Erika Duffell
KGKonstantinos Gountas
Konstantinos Gountas
BBBenjamin Bluemel
Benjamin Bluemel
Georgios NikolopoulosGeorgios Nikolopoulos
Georgios Nikolopoulos
Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. 10.13039/501100000805 ECDC .

1 January 2013 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
AAAnne M. Audelin
Anne M. Audelin
SCSusan A. Cowan
Susan A. Cowan
NONiels Obel
Niels Obel
CNClaus Nielsen
Claus Nielsen
LJLouise B. Jørgensen
Louise B. Jørgensen
JGJan Gerstoft
Jan Gerstoft
Background: In Denmark, 300 new individuals are diagnosed with HIV every year, despite decades of public health campaigns aimed to raise awareness of potential risk behavior for HIV transmission. It is important to identify the driving forces of the epidemic, to enable more targeted campaigns. The role of very late presenters (VLPs, defined by a CD4 T-cell count of <200 cells/μL at the time of diagnosis) in driving the epidemic is currently not known and was investigated in this study. Methods: We performed phylogenetic analysis to identify potential transmission clusters. One thousand five hundred fifteen partial polymerase sequences from 1515 newly diagnosed individuals in Denmark for whom clinical and epidemiological data existed were included in the study. Results: We identified 46 epidemic clusters, including a total of 502 patients. Median cluster size was 7 patients (range, 4–82). Of the 460 VLPs, 20% were included in a cluster. Through multivariate analysis, it was found that the clusters mainly consisted of Danish individuals with homosexual and intravenous drug use risk behavior, infected in Denmark with subtype B. Large clusters contained significantly more homosexual transmission events, characterized by primary infections, younger age, higher CD4 cell count, and lower viral load compared with the small clusters that contained mostly heterosexual transmission events and VLP. Conclusion: Danish HIV epidemic is driven mainly by younger homosexual men diagnosed during primary HIV infection. VLPs appear more frequently in smaller clusters or as single branches in the phylogeny. The VLP contribution is not of significant importance from a transmission standpoint.